Avidity Biosciences Inc
RNAM
Hisse Senetlerindeki Sıralama
#2070
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Hisse Fiyatı
$71.34
Son senkronizasyon: 2026-03-03
Piyasa Değeri
$9.84B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
-
Ülke
US
Ticaret Avidity Biosciences Inc (RNAM)
Kategori
Healthcare
Avidity Biosciences Inc (RNAM) için temettü verimi geçmişi
Avidity Biosciences Inc (hisse sembolü: RNAM) temettü verimi (TTM) 2024-12-31 itibariyle: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
Avidity Biosciences Inc (RNAM) için 2018 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
| Yıl | Temettü Verimi | Değiştir |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Benzer şirketler veya rakiplerin temettü verimi (TTM)
| Şirket | Temettü Verimi | Ülke |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.07% |
AU
|
|
| 0.56% |
BE
|
|
| 0.00% |
NL
|
